Rau's Respiratory Care Pharmacology, 11th Edition
TEST BANK
1,200 Original Questions • Correct Answer After Every Question • Detailed Teaching Rationale
Aligned with the textbook by Douglas S. Gardenhire
Complete Chapters 1–23
Page 1
,Coverage
• Chapter 1: Introduction to Respiratory Care Pharmacology — 53 questions
• Chapter 2: Principles of Drug Action — 53 questions
• Chapter 3: Administration of Aerosolized Agents — 53 questions
• Chapter 4: Calculating Drug Doses — 53 questions
• Chapter 5: The Central and Peripheral Nervous Systems — 52 questions
• Chapter 6: Adrenergic (Sympathomimetic) Bronchodilators — 52 questions
• Chapter 7: Anticholinergic (Parasympatholytic) Bronchodilators — 52 questions
• Chapter 8: Xanthines — 52 questions
• Chapter 9: Mucus-Controlling Drug Therapy — 52 questions
• Chapter 10: Surfactant Agents — 52 questions
• Chapter 11: Corticosteroids in Respiratory Care — 52 questions
• Chapter 12: Nonsteroidal Antiasthma Agents — 52 questions
• Chapter 13: Aerosolized Antiinfective Agents — 52 questions
• Chapter 14: Antimicrobial Agents — 52 questions
• Chapter 15: Cold and Cough Agents — 52 questions
• Chapter 16: Selected Agents of Pulmonary Value — 52 questions
• Chapter 17: Neonatal and Pediatric Aerosolized Drug Therapy — 52 questions
• Chapter 18: Skeletal Muscle Relaxants (Neuromuscular Blocking Agents) — 52 questions
• Chapter 19: Diuretic Agents — 52 questions
• Chapter 20: Drugs Affecting the Central Nervous System — 52 questions
• Chapter 21: Vasopressors, Inotropes, and Antiarrhythmic Agents — 52 questions
• Chapter 22: Drugs Affecting Circulation: Antihypertensives, Antianginals, Antithrombotics — 52
questions
• Chapter 23: Sleep and Sleep Pharmacology — 52 questions
Page 2
,Chapter 1: Introduction to Respiratory Care Pharmacology
1. Which option best identifies an adverse-effect or safety concern associated with nitroglycerin?
A. Blood pressure, symptoms, and recent PDE-5 inhibitor use.
B. Sit down before sublingual use and seek emergency help for persistent chest pain.
C. Angina and selected acute coronary/heart-failure settings.
D. Headache, hypotension, dizziness.
Answer: D — Headache, hypotension, dizziness.
Detailed rationale: The adverse-effect or safety concern highlighted for nitroglycerin is: headache,
hypotension, dizziness. The remaining options describe related pharmacologic concepts, teaching points,
or monitoring considerations but do not answer the safety implication asked in the stem. Clinical
reasoning: first identify exactly what the stem is testing—such as drug class, mechanism, indication,
expected effect, adverse reaction, contraindication, monitoring priority, or patient teaching—then select
the option that answers that dimension most directly. Safety connection: the correct response links
pharmacology knowledge to prevention of medication error, recognition of toxicity or deterioration, and
appropriate follow-up. Why the distractors are incorrect: some alternatives describe a related
pharmacologic property or safety principle, while others do not answer the clinical dimension requested
or conflict with safe medication-use principles.
2. Which statement best explains the pharmacologic relevance or appropriate clinical use of dornase
alfa?
A. Reduce sputum viscosity in cystic fibrosis.
B. Not interchangeable with simple saline nebulization.
C. Voice alteration, pharyngitis, and rash.
D. Pulmonary function and symptom response.
Answer: A — Reduce sputum viscosity in cystic fibrosis.
Detailed rationale: The pharmacologic relevance or clinical use highlighted for dornase alfa is: reduce
sputum viscosity in cystic fibrosis. This distinction separates the relevant concept or therapeutic purpose
from adverse effects, monitoring requirements, and precautions. Clinical reasoning: first identify exactly
what the stem is testing—such as drug class, mechanism, indication, expected effect, adverse reaction,
contraindication, monitoring priority, or patient teaching—then select the option that answers that
dimension most directly. Safety connection: the correct response links pharmacology knowledge to
prevention of medication error, recognition of toxicity or deterioration, and appropriate follow-up. Why
the distractors are incorrect: some alternatives describe a related pharmacologic property or safety
principle, while others do not answer the clinical dimension requested or conflict with safe medication-
use principles.
Page 3
, 3. Which option best identifies an adverse-effect or safety concern associated with cromolyn?
A. Symptom prevention.
B. Prophylaxis of selected allergic airway symptoms.
C. Use prophylactically; it does not reverse acute bronchospasm.
D. Cough and throat irritation.
Answer: D — Cough and throat irritation.
Detailed rationale: The adverse-effect or safety concern highlighted for cromolyn is: cough and throat
irritation. The remaining options describe related pharmacologic concepts, teaching points, or
monitoring considerations but do not answer the safety implication asked in the stem. Clinical reasoning:
first identify exactly what the stem is testing—such as drug class, mechanism, indication, expected
effect, adverse reaction, contraindication, monitoring priority, or patient teaching—then select the option
that answers that dimension most directly. Safety connection: the correct response links pharmacology
knowledge to prevention of medication error, recognition of toxicity or deterioration, and appropriate
follow-up. Why the distractors are incorrect: some alternatives describe a related pharmacologic
property or safety principle, while others do not answer the clinical dimension requested or conflict with
safe medication-use principles.
4. In this situation, which patient-teaching point is most important for heparin?
A. Clinician monitoring: platelet count, bleeding, and aPTT/anti-Xa according to regimen.
B. Report bleeding and avoid unnecessary trauma.
C. Prevention and treatment of thrombosis.
D. Potentiates antithrombin to inhibit clotting factors, especially thrombin and factor Xa.
Answer: B — Report bleeding and avoid unnecessary trauma.
Detailed rationale: The most relevant patient-teaching or safety point associated with heparin is: report
bleeding and avoid unnecessary trauma. This teaching reduces preventable harm and supports adherence.
The other options are pharmacology facts or clinician-monitoring responsibilities, not the requested
patient-teaching point. Clinical reasoning: first identify exactly what the stem is testing—such as drug
class, mechanism, indication, expected effect, adverse reaction, contraindication, monitoring priority, or
patient teaching—then select the option that answers that dimension most directly. Safety connection:
the correct response links pharmacology knowledge to prevention of medication error, recognition of
toxicity or deterioration, and appropriate follow-up. Why the distractors are incorrect: some alternatives
describe a related pharmacologic property or safety principle, while others do not answer the clinical
dimension requested or conflict with safe medication-use principles.
5. Which mechanism best explains the expected effect of salmeterol?
A. Provides prolonged beta2-mediated bronchial smooth-muscle relaxation.
Page 4
TEST BANK
1,200 Original Questions • Correct Answer After Every Question • Detailed Teaching Rationale
Aligned with the textbook by Douglas S. Gardenhire
Complete Chapters 1–23
Page 1
,Coverage
• Chapter 1: Introduction to Respiratory Care Pharmacology — 53 questions
• Chapter 2: Principles of Drug Action — 53 questions
• Chapter 3: Administration of Aerosolized Agents — 53 questions
• Chapter 4: Calculating Drug Doses — 53 questions
• Chapter 5: The Central and Peripheral Nervous Systems — 52 questions
• Chapter 6: Adrenergic (Sympathomimetic) Bronchodilators — 52 questions
• Chapter 7: Anticholinergic (Parasympatholytic) Bronchodilators — 52 questions
• Chapter 8: Xanthines — 52 questions
• Chapter 9: Mucus-Controlling Drug Therapy — 52 questions
• Chapter 10: Surfactant Agents — 52 questions
• Chapter 11: Corticosteroids in Respiratory Care — 52 questions
• Chapter 12: Nonsteroidal Antiasthma Agents — 52 questions
• Chapter 13: Aerosolized Antiinfective Agents — 52 questions
• Chapter 14: Antimicrobial Agents — 52 questions
• Chapter 15: Cold and Cough Agents — 52 questions
• Chapter 16: Selected Agents of Pulmonary Value — 52 questions
• Chapter 17: Neonatal and Pediatric Aerosolized Drug Therapy — 52 questions
• Chapter 18: Skeletal Muscle Relaxants (Neuromuscular Blocking Agents) — 52 questions
• Chapter 19: Diuretic Agents — 52 questions
• Chapter 20: Drugs Affecting the Central Nervous System — 52 questions
• Chapter 21: Vasopressors, Inotropes, and Antiarrhythmic Agents — 52 questions
• Chapter 22: Drugs Affecting Circulation: Antihypertensives, Antianginals, Antithrombotics — 52
questions
• Chapter 23: Sleep and Sleep Pharmacology — 52 questions
Page 2
,Chapter 1: Introduction to Respiratory Care Pharmacology
1. Which option best identifies an adverse-effect or safety concern associated with nitroglycerin?
A. Blood pressure, symptoms, and recent PDE-5 inhibitor use.
B. Sit down before sublingual use and seek emergency help for persistent chest pain.
C. Angina and selected acute coronary/heart-failure settings.
D. Headache, hypotension, dizziness.
Answer: D — Headache, hypotension, dizziness.
Detailed rationale: The adverse-effect or safety concern highlighted for nitroglycerin is: headache,
hypotension, dizziness. The remaining options describe related pharmacologic concepts, teaching points,
or monitoring considerations but do not answer the safety implication asked in the stem. Clinical
reasoning: first identify exactly what the stem is testing—such as drug class, mechanism, indication,
expected effect, adverse reaction, contraindication, monitoring priority, or patient teaching—then select
the option that answers that dimension most directly. Safety connection: the correct response links
pharmacology knowledge to prevention of medication error, recognition of toxicity or deterioration, and
appropriate follow-up. Why the distractors are incorrect: some alternatives describe a related
pharmacologic property or safety principle, while others do not answer the clinical dimension requested
or conflict with safe medication-use principles.
2. Which statement best explains the pharmacologic relevance or appropriate clinical use of dornase
alfa?
A. Reduce sputum viscosity in cystic fibrosis.
B. Not interchangeable with simple saline nebulization.
C. Voice alteration, pharyngitis, and rash.
D. Pulmonary function and symptom response.
Answer: A — Reduce sputum viscosity in cystic fibrosis.
Detailed rationale: The pharmacologic relevance or clinical use highlighted for dornase alfa is: reduce
sputum viscosity in cystic fibrosis. This distinction separates the relevant concept or therapeutic purpose
from adverse effects, monitoring requirements, and precautions. Clinical reasoning: first identify exactly
what the stem is testing—such as drug class, mechanism, indication, expected effect, adverse reaction,
contraindication, monitoring priority, or patient teaching—then select the option that answers that
dimension most directly. Safety connection: the correct response links pharmacology knowledge to
prevention of medication error, recognition of toxicity or deterioration, and appropriate follow-up. Why
the distractors are incorrect: some alternatives describe a related pharmacologic property or safety
principle, while others do not answer the clinical dimension requested or conflict with safe medication-
use principles.
Page 3
, 3. Which option best identifies an adverse-effect or safety concern associated with cromolyn?
A. Symptom prevention.
B. Prophylaxis of selected allergic airway symptoms.
C. Use prophylactically; it does not reverse acute bronchospasm.
D. Cough and throat irritation.
Answer: D — Cough and throat irritation.
Detailed rationale: The adverse-effect or safety concern highlighted for cromolyn is: cough and throat
irritation. The remaining options describe related pharmacologic concepts, teaching points, or
monitoring considerations but do not answer the safety implication asked in the stem. Clinical reasoning:
first identify exactly what the stem is testing—such as drug class, mechanism, indication, expected
effect, adverse reaction, contraindication, monitoring priority, or patient teaching—then select the option
that answers that dimension most directly. Safety connection: the correct response links pharmacology
knowledge to prevention of medication error, recognition of toxicity or deterioration, and appropriate
follow-up. Why the distractors are incorrect: some alternatives describe a related pharmacologic
property or safety principle, while others do not answer the clinical dimension requested or conflict with
safe medication-use principles.
4. In this situation, which patient-teaching point is most important for heparin?
A. Clinician monitoring: platelet count, bleeding, and aPTT/anti-Xa according to regimen.
B. Report bleeding and avoid unnecessary trauma.
C. Prevention and treatment of thrombosis.
D. Potentiates antithrombin to inhibit clotting factors, especially thrombin and factor Xa.
Answer: B — Report bleeding and avoid unnecessary trauma.
Detailed rationale: The most relevant patient-teaching or safety point associated with heparin is: report
bleeding and avoid unnecessary trauma. This teaching reduces preventable harm and supports adherence.
The other options are pharmacology facts or clinician-monitoring responsibilities, not the requested
patient-teaching point. Clinical reasoning: first identify exactly what the stem is testing—such as drug
class, mechanism, indication, expected effect, adverse reaction, contraindication, monitoring priority, or
patient teaching—then select the option that answers that dimension most directly. Safety connection:
the correct response links pharmacology knowledge to prevention of medication error, recognition of
toxicity or deterioration, and appropriate follow-up. Why the distractors are incorrect: some alternatives
describe a related pharmacologic property or safety principle, while others do not answer the clinical
dimension requested or conflict with safe medication-use principles.
5. Which mechanism best explains the expected effect of salmeterol?
A. Provides prolonged beta2-mediated bronchial smooth-muscle relaxation.
Page 4
